WO2005083385A3 - Method of evaluating the therapeutic potential of a vaccine for mucosal administration - Google Patents

Method of evaluating the therapeutic potential of a vaccine for mucosal administration Download PDF

Info

Publication number
WO2005083385A3
WO2005083385A3 PCT/DK2005/000123 DK2005000123W WO2005083385A3 WO 2005083385 A3 WO2005083385 A3 WO 2005083385A3 DK 2005000123 W DK2005000123 W DK 2005000123W WO 2005083385 A3 WO2005083385 A3 WO 2005083385A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic potential
vaccine
evaluating
mucosal administration
vaccination
Prior art date
Application number
PCT/DK2005/000123
Other languages
French (fr)
Other versions
WO2005083385A2 (en
Inventor
Hans-Henrik Ipsen
Maerkedahl Lise Lund
Henrik Hugo Jacobi
Original Assignee
Alk Abello As
Hans-Henrik Ipsen
Maerkedahl Lise Lund
Henrik Hugo Jacobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As, Hans-Henrik Ipsen, Maerkedahl Lise Lund, Henrik Hugo Jacobi filed Critical Alk Abello As
Priority to AU2005217696A priority Critical patent/AU2005217696B2/en
Priority to BRPI0508078-9A priority patent/BRPI0508078A/en
Priority to EP05706785A priority patent/EP1718974A2/en
Priority to RU2006134031/15A priority patent/RU2006134031A/en
Priority to JP2007500050A priority patent/JP2007524096A/en
Priority to CA002556557A priority patent/CA2556557A1/en
Publication of WO2005083385A2 publication Critical patent/WO2005083385A2/en
Publication of WO2005083385A3 publication Critical patent/WO2005083385A3/en
Priority to IL177703A priority patent/IL177703A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The invention relates to a method of evaluating the therapeutic potential of a vaccination program comprising a vaccine for mucosal administration comprising one or more antigens and a vaccination protocol, the method comprising a) subjecting at least one test individual to the vaccination program, b) measuring the level of a biomarker antibody selected from the group consisting of IgA, IgG, IgE and IgX specific to the antigen in a biological sample from the test individual, and c) using the measurements obtained to evaluate the therapeutic potential of the vaccination program.
PCT/DK2005/000123 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration WO2005083385A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005217696A AU2005217696B2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
BRPI0508078-9A BRPI0508078A (en) 2004-02-26 2005-02-24 method for assessing the therapeutic potential of a mucosal vaccine
EP05706785A EP1718974A2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
RU2006134031/15A RU2006134031A (en) 2004-02-26 2005-02-24 METHOD FOR EVALUATING THE VACCINE THERAPEUTIC CAPACITY FOR INTRODUCTION THROUGH Mucous membranes
JP2007500050A JP2007524096A (en) 2004-02-26 2005-02-24 Method for evaluating the therapeutic potential of vaccines for mucosal administration
CA002556557A CA2556557A1 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration
IL177703A IL177703A0 (en) 2004-02-26 2006-08-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54845404P 2004-02-26 2004-02-26
DKPA200400310 2004-02-26
US60/548,454 2004-02-26
DKPA200400310 2004-02-26
US55909504P 2004-04-02 2004-04-02
US60/559,095 2004-04-02

Publications (2)

Publication Number Publication Date
WO2005083385A2 WO2005083385A2 (en) 2005-09-09
WO2005083385A3 true WO2005083385A3 (en) 2005-11-17

Family

ID=34915878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000123 WO2005083385A2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Country Status (8)

Country Link
EP (1) EP1718974A2 (en)
JP (1) JP2007524096A (en)
AU (1) AU2005217696B2 (en)
BR (1) BRPI0508078A (en)
CA (1) CA2556557A1 (en)
IL (1) IL177703A0 (en)
RU (1) RU2006134031A (en)
WO (1) WO2005083385A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556557A1 (en) * 2004-02-26 2005-09-09 Alk Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
EP1974745B1 (en) 2007-03-28 2011-08-31 Alk-Abelló A/S Use of an adjuvanted allergy vaccine formulation for subcutaneous administration
CN101674845A (en) * 2007-03-28 2010-03-17 阿尔克-阿贝洛有限公司 The purposes that is used for the adjuvanted allergy vaccine formulation of parenteral
DE202008006598U1 (en) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergy vaccine formulation for mucosal administration
US11686733B2 (en) 2016-05-13 2023-06-27 Applied Medical Enzyme Research Institute Corporation Method for collecting data to predict risk of developing allergies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021031A1 (en) * 1991-05-10 1992-11-26 Alain De Weck PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
WO1998030586A2 (en) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2000040713A1 (en) * 1999-01-06 2000-07-13 Mcmaster University Method of preventing immune and hypersensitivity reactions
WO2002053595A1 (en) * 2000-12-29 2002-07-11 Pharmacia Diagnostics Ab Group 2 allergen specific ige-fabs and igg molecules and use thereof
UA62780A (en) * 2003-05-22 2003-12-15 Univ Oo Bohomolets Nat Medical Method for estimating efficiency of vaccination against diphtheria in children with allergic diathesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010053162A (en) * 1998-06-24 2001-06-25 알크-아벨로 에이/에스 Method of detecting an antibody in a liquid sample
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method
CA2556557A1 (en) * 2004-02-26 2005-09-09 Alk Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021031A1 (en) * 1991-05-10 1992-11-26 Alain De Weck PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
WO1998030586A2 (en) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2000040713A1 (en) * 1999-01-06 2000-07-13 Mcmaster University Method of preventing immune and hypersensitivity reactions
WO2002053595A1 (en) * 2000-12-29 2002-07-11 Pharmacia Diagnostics Ab Group 2 allergen specific ige-fabs and igg molecules and use thereof
UA62780A (en) * 2003-05-22 2003-12-15 Univ Oo Bohomolets Nat Medical Method for estimating efficiency of vaccination against diphtheria in children with allergic diathesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; BYCHKOVA , N H: "Method for estimating efficiency of vaccination against diphteria in children with allergic diathesis", XP002344424 *

Also Published As

Publication number Publication date
WO2005083385A2 (en) 2005-09-09
IL177703A0 (en) 2006-12-31
BRPI0508078A (en) 2007-07-17
AU2005217696A1 (en) 2005-09-09
CA2556557A1 (en) 2005-09-09
RU2006134031A (en) 2008-04-10
AU2005217696B2 (en) 2008-02-14
JP2007524096A (en) 2007-08-23
EP1718974A2 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
Khoury et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
Corbett et al. Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates
Versteegh et al. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis
MX2007014815A (en) Improved immunoassay methods.
WO2005083385A3 (en) Method of evaluating the therapeutic potential of a vaccine for mucosal administration
WO2007025044A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
Paulke-Korinek et al. Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination
NO20076662L (en) Detection of a malantigen independent of the presence or absence of a corresponding therapeutic antibody
WO2012100070A3 (en) Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
Krämer et al. The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines
IN2009CN03372A (en)
Prelog et al. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination
WO2007050095A3 (en) Improved vaccines and methods for using the same
Muhamuda et al. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans
Berbers et al. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens
WO2008073895A3 (en) Methods and devices for testing saliva
HK1094036A1 (en) Evaluation of adjuvanted vaccines
Rendi-Wagner et al. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up
Cliquet et al. Standardisation and establishment of a rabies ELISA test in European laboratories for assessing the efficacy of oral fox vaccination campaigns
Korimbocus et al. Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use
WO2005106476A3 (en) Method for diagnosing infectious diseases
Agrati et al. Coordinate induction of humoral and spike specific T-cell response in a cohort of Italian health care workers receiving BNT162b2 mRNA vaccine. Microorganisms 2021; 9: 1315
WO2005119259A3 (en) Population based prediction methods for immune response determinations and methods for verifying immunological response data
Mohanram et al. Improved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus macaques
Hr et al. Analysis of specific antibody and cellular immune response to first-dose measles vaccine Edmonston-Zagreb in 9-month-old infants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2556557

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 177703

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 4897/DELNP/2006

Country of ref document: IN

Ref document number: PA/a/2006/009737

Country of ref document: MX

Ref document number: 2007500050

Country of ref document: JP

Ref document number: 2005217696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005706785

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006/07376

Country of ref document: ZA

Ref document number: 200607376

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005217696

Country of ref document: AU

Date of ref document: 20050224

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005217696

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006134031

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580011627.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005706785

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0508078

Country of ref document: BR